STEVE ASELAGE Insider Trading

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for STEVE ASELAGE.

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of STEVE ASELAGE. STEVE ASELAGE is a Director in BIOCRYST PHARMACEUTICALS INC ($BCRX) and a EVP, Global Commercial Ops in CTI BIOPHARMA CORP ($CTIC) and a in Acer Therapeutics Inc. ($OPXA) and a Director in Acer Therapeutics Inc. ($OPXA) and an Chief Executive Officer in Retrophin, Inc. ($RTRX) and a Director in Retrophin, Inc. ($RTRX).

Over the past year STEVE ASELAGE has been an insider in 3 companies. The total value of shares held by STEVE ASELAGE in these companies amounts to $5,199,649.

STEVE ASELAGE Director
Acer Therapeutics Inc.
Director
BIOCRYST PHARMACEUTICALS INC
EVP, Global Commercial Ops
CTI BIOPHARMA CORP
Director, Chief Executive Officer
Retrophin, Inc.
$ 5199649 The total value of shares held by STEVE ASELAGE
Insider Rank

STEVE ASELAGE ranks 5,659 out of 350,000 insiders. Go to Insider Ranking to see more.

Address: 501 ELLIOTT AVE W. SUITE 400 SEATTLE 98119 WA

Companies in which STEVE ASELAGE is an Insider

Acer Therapeutics Inc.

Trading Symbol: ACER
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of STEVE ASELAGE: Director
Holdings: 13,905 shares
Current Value: $14,183
Latest Transaction: Feb 05 2019
$ACER Market Capitalization: $7.21M
$ACER Previous Close: $1.02

Last 4 weeks trend: STRONG BUY
Last 3 months trend: STRONG BUY View transactions

Last 3 Months Overview:
Buy: 2x
Sell: 0x
Shares Bought: 13,905
Shares Sold: 0
Share Difference: +13,905
Value Difference: -$24,000

BIOCRYST PHARMACEUTICALS INC

Trading Symbol: BCRX
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of STEVE ASELAGE: Director
Holdings: 2,000 shares
Current Value: $11,340
Latest Transaction: Mar 14 2019
$BCRX Market Capitalization: $427.06M
$BCRX Previous Close: $5.67

Last 4 weeks trend: BUY
Last 3 months trend: BUY View transactions

Last 3 Months Overview:
Buy: 1x
Sell: 0x
Shares Bought: 2,000
Shares Sold: 0
Share Difference: +2,000
Value Difference: -$16,600

CTI BIOPHARMA CORP

Trading Symbol: CTIC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of STEVE ASELAGE: EVP, Global Commercial Ops
Holdings: 6,000 shares
Current Value: $28,020
Latest Transaction: Feb 20 2004
$CTIC Market Capitalization: $129.36M
$CTIC Previous Close: $4.67

Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions

Retrophin, Inc.

Trading Symbol: RTRX
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of STEVE ASELAGE: Director, Chief Executive Officer
Holdings: 257,804 shares
Current Value: $5,174,126
Latest Transaction: May 16 2019
$RTRX Market Capitalization: $766.34M
$RTRX Previous Close: $20.07

Last 4 weeks trend: STRONG SELL
Last 3 months trend: STRONG SELL View transactions

Last 3 Months Overview:
Buy: 6x
Sell: 20x
Shares Bought: 62,952
Shares Sold: 141,242
Share Difference: -78,290
Value Difference: +$1,189,192

Latest Insider Trading Transactions of STEVE ASELAGE

Sentiment: All, ACER, BCRX, CTIC, RTRX

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
May 16 2019RTRXRetrophin, Inc.ASELAGE STEVEDirectorSellS17.821,83832,753255,966257.8 K to 256 K (-0.71 %)
May 16 2019RTRXRetrophin, Inc.ASELAGE STEVEDirectorSellS17.791,83832,698257,804259.6 K to 257.8 K (-0.71 %)
May 10 2019RTRXRetrophin, Inc.ASELAGE STEVEDirectorOption ExerciseA17.948,000143,5208,000
May 10 2019RTRXRetrophin, Inc.ASELAGE STEVEDirectorGrantA0.002,0000259,642257.6 K to 259.6 K (+0.78 %)
Mar 14 2019BCRXBIOCRYST PHARMACEU ...ASELAGE STEVEDirectorBuyP8.302,00016,6002,0000 to 2 K
Feb 13 2019RTRXRetrophin, Inc.ASELAGE STEVEChief Executive Off ...SellS21.501,06522,898257,642258.7 K to 257.6 K (-0.41 %)
Feb 13 2019RTRXRetrophin, Inc.ASELAGE STEVEChief Executive Off ...SellS21.381,06522,770258,707259.8 K to 258.7 K (-0.41 %)

View all STEVE ASELAGE insider transactions.